Primary antibodies and sources
| Antibody . | Source . | Dilution . |
|---|---|---|
| CD20 (L26) | Dako, Carpinteria, CA | 1:200 |
| CD3 | Dako | 1:100 |
| CD10 | Novacastra, Newcastle upon Tyne, United Kingdom | 1:40 |
| MIB1 | Dako | 1:50 |
| BCL-2 | Dako | 1:20 |
| Kappa | Dako | 1:25 000 |
| Lambda | Dako | 1:25 000 |
| CD5 | Novacastra | 1:50 |
| IgD | Dako | 1:800 |
| CD23 | The Binding Site, Birmingham, United Kingdom | 1:20 |
| Cyclin D1 | Novacastra | 1:10 |
| Bcl-6 | Dako | 1:20 |
| Antibody . | Source . | Dilution . |
|---|---|---|
| CD20 (L26) | Dako, Carpinteria, CA | 1:200 |
| CD3 | Dako | 1:100 |
| CD10 | Novacastra, Newcastle upon Tyne, United Kingdom | 1:40 |
| MIB1 | Dako | 1:50 |
| BCL-2 | Dako | 1:20 |
| Kappa | Dako | 1:25 000 |
| Lambda | Dako | 1:25 000 |
| CD5 | Novacastra | 1:50 |
| IgD | Dako | 1:800 |
| CD23 | The Binding Site, Birmingham, United Kingdom | 1:20 |
| Cyclin D1 | Novacastra | 1:10 |
| Bcl-6 | Dako | 1:20 |
All antibodies used in this study are monoclonal except CD3, kappa, and lambda.